{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:44:48Z","timestamp":1792118688419,"version":"4.4.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40265-025-02261-2","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:29:05Z","timestamp":1764574145000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don\u2019t Know"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8895-4903","authenticated-orcid":false,"given":"Edward K.","family":"Silberman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"issue":"6","key":"2261_CR1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP18m12174","volume":"79","author":"C Blanco","year":"2018","unstructured":"Blanco C, Han B, Jones CM, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the US. J Clin Psychiatry. 2018;79(6):18m12174. https:\/\/doi.org\/10.4088\/JCP18m12174.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"2261_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsyhiatry.2014.1763.","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatr. 2015;72(2):136\u201342. https:\/\/doi.org\/10.1001\/jamapsyhiatry.2014.1763.","journal-title":"JAMA Psychiatr"},{"issue":"5","key":"2261_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000524772","volume":"91","author":"V Starcevic","year":"2022","unstructured":"Starcevic V. Representation of benzodiazepines in treatment guidelines: the paradox of undesirable objectivity. Psychother Psychosom. 2022;91(5):295\u20139. https:\/\/doi.org\/10.1159\/000524772.","journal-title":"Psychother Psychosom"},{"issue":"6","key":"2261_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1159\/000493015","volume":"87","author":"R Balon","year":"2018","unstructured":"Balon R, Rafanelli C, Sonino N. Benzodiazepines: a valuable tool in the management of cardiovascular conditions. Psychother Psychosom. 2018;87(6):327\u201330.","journal-title":"Psychother Psychosom"},{"issue":"4","key":"2261_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11940-016-0401-x","volume":"18","author":"JG Ochoa","year":"2016","unstructured":"Ochoa JG, Kilgo WA. The role of benzodiazepines in the treatment of epilepsy. Curr Treat Opt Neurol. 2016;18(4):18.","journal-title":"Curr Treat Opt Neurol"},{"issue":"9","key":"2261_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","volume":"28","author":"J Wick","year":"2013","unstructured":"Wick J. The history of benzodiazepines. Consultant Pharm. 2013;28(9):538\u201348.","journal-title":"Consultant Pharm"},{"issue":"1","key":"2261_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1468-0009.2010.00591.x","volume":"88","author":"AV Horwitz","year":"2010","unstructured":"Horwitz AV. How an age of anxiety became an age of depression. Milbank Q. 2010;88(1):112\u201338.","journal-title":"Milbank Q"},{"issue":"7","key":"2261_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jama.2013.272","volume":"309","author":"CM Jones","year":"2013","unstructured":"Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013;309(7):657\u20139.","journal-title":"JAMA"},{"issue":"4","key":"2261_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0031-6997(25)06658-X","volume":"39","author":"JH Woods","year":"1987","unstructured":"Woods JH, Katz JL, Winger G. Abuse liability of benzodiazepines. Pharmacol Rev. 1987;39(4):251\u2013413.","journal-title":"Pharmacol Rev"},{"key":"2261_CR10","volume-title":"Benzodiazepine dependence, toxicity, and abuse: a task force report of the American Psychiatric Association","author":"American Psychiatric Association","year":"1990","unstructured":"American Psychiatric Association. Benzodiazepine dependence, toxicity, and abuse: a task force report of the American Psychiatric Association. American Psychiatric Pub; 1990."},{"issue":"5","key":"2261_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1159\/000524400","volume":"91","author":"SL Dubovsky","year":"2022","unstructured":"Dubovsky SL, Marshall D. Benzodiazepines remain important therapeutic options in psychiatric practice. Psychother Psychosom. 2022;91(5):307\u201334. https:\/\/doi.org\/10.1159\/000524400.","journal-title":"Psychother Psychosom"},{"issue":"5","key":"2261_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/JCP.0b013e31822d0012","volume":"31","author":"S Moylan","year":"2011","unstructured":"Moylan S, Staples J, Ward SA, Rogerson J, Stein DJ, Berk M. The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder. J Clin Psychopharmacol. 2011;31(5):647\u201352.","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"2261_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000437201","volume":"84","author":"F Cosci","year":"2015","unstructured":"Cosci F, Guidi J, Balon R, Fava GA. Clinical methodology matters in epidemiology: not all benzodiazepines are the same. Psychother Psychosom. 2015;84(5):262\u20134.","journal-title":"Psychother Psychosom"},{"issue":"7","key":"2261_CR14","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1080\/15622975.2018.1500031","volume":"20","author":"K Rickels","year":"2019","unstructured":"Rickels K, Moeller HJ. Benzodiazepines in anxiety disorders: reassessment of usefulness and safety. World J Biol Psychiatry. 2019;20(7):514\u20138. https:\/\/doi.org\/10.1080\/15622975.2018.1500031.","journal-title":"World J Biol Psychiatry"},{"issue":"5","key":"2261_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/YIC0000000000000276","volume":"34","author":"M Shinfuku","year":"2019","unstructured":"Shinfuku M, Kishimoto T, Uchida H, Suzuki T, Mimura M, Kikuchi T. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019;34(5):211\u201321. https:\/\/doi.org\/10.1097\/YIC0000000000000276.","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"2261_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/PRA.0000000000000091","volume":"21","author":"J Guina","year":"2015","unstructured":"Guina J, Rossetter SR, DeRhodes BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatric Pract. 2015;21(4):281\u2013303.","journal-title":"J Psychiatric Pract"},{"key":"2261_CR17","unstructured":"Hewlett WA. Benzodiazepines in the treatment of obsessive compulsive disorder. In: Obsessive compulsive disorder, contemporary issues in treatment. Lawrence Erlbaum Associates New York, 2000; pp. 405-429."},{"issue":"6","key":"2261_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/0003353198","volume":"82","author":"E Offidani","year":"2013","unstructured":"Offidani E, Guidi J, Tomba E, Fava GA. Efficacy and tolerability of benzodiazepines versus antidepressants in anxiety disorders: a systematic review and meta-analysis. Psychother Psychosom. 2013;82(6):355\u201362. https:\/\/doi.org\/10.1159\/0003353198.","journal-title":"Psychother Psychosom"},{"issue":"8","key":"2261_CR19","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/14656566.2018.1472767","volume":"19","author":"AF Gomez","year":"2018","unstructured":"Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother. 2018;19(8):883\u201394.","journal-title":"Expert Opin Pharmacother"},{"key":"2261_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2021.102664","volume":"60","author":"Y Du","year":"2021","unstructured":"Du Y, Du B, Diao Y, Yin Z, Li J, Shu Y, et al. Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: a systematic review and network meta-analysis. Asian J Psychiatr. 2021;60:102664. https:\/\/doi.org\/10.1016\/j.ajp.2021.102664.","journal-title":"Asian J Psychiatr"},{"issue":"8","key":"2261_CR21","first-page":"293","volume":"49","author":"R Hoehn-Saric","year":"1988","unstructured":"Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry. 1988;49(8):293\u2013301.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"2261_CR22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1517\/14656566.2015.1059424","volume":"16","author":"JA Reinhold","year":"2015","unstructured":"Reinhold JA, Rickels K. Pharmacological treatment for generalized anxiety disorder in adults: an update. Expert Opin Pharmacother. 2015;16(11):1669\u201381. https:\/\/doi.org\/10.1517\/14656566.2015.1059424.","journal-title":"Expert Opin Pharmacother"},{"key":"2261_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/euroneuro.2023.008","volume":"76","author":"F Rossano","year":"2023","unstructured":"Rossano F, Caiazza C, Zotti N, Viacava L, Irano A, Solini N, et al. The efficacy, safety, and adverse events of azapirones in anxiety disorders: a systematic review and meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol. 2023;76:23\u201351. https:\/\/doi.org\/10.1016\/euroneuro.2023.008.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"2261_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/YIC.0000000000000147","volume":"32","author":"MB Generoso","year":"2017","unstructured":"Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017;32(1):49\u201355.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"2261_CR25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/0269881115612236","volume":"30","author":"SA Steenen","year":"2016","unstructured":"Steenen SA, Van Wijk AJ, Van Der Heijden GJ, van Westrhenen R, de Lange J, de Jongh A. Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis. J Psychopharmacol. 2016;30(2):128\u201339. https:\/\/doi.org\/10.1177\/0269881115612236.","journal-title":"J Psychopharmacol"},{"issue":"10","key":"2261_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2146\/ajhp060640","volume":"65","author":"S Passarella","year":"2008","unstructured":"Passarella S, Duong MT. Diagnosis and treatment of insomnia. Am J Health-Syst Pharm. 2008;65(10):927\u201334. https:\/\/doi.org\/10.2146\/ajhp060640.","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"2261_CR27","first-page":"24","volume":"19","author":"W Sieghart","year":"1994","unstructured":"Sieghart W. Pharmacology of benzodiazepine receptors: an update. J Psychiatry Neurosci. 1994;19(1):24.","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"2261_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jsmc.2020.02.002","volume":"15","author":"S Dujardin","year":"2020","unstructured":"Dujardin S, Pijpers A, Pevernagie D. Prescription drugs used in insomnia. Sleep Med Clin. 2020;15(2):133\u201345.","journal-title":"Sleep Med Clin"},{"issue":"7","key":"2261_CR29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.2165\/00003495-200565070-00003","volume":"65","author":"S Wilson","year":"2005","unstructured":"Wilson S, Argyropoulos S. Antidepressants and sleep: a qualitative review of the literature. Drugs. 2005;65(7):927\u201347.","journal-title":"Drugs"},{"issue":"6319","key":"2261_CR30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/bmj.284.6319.860","volume":"284","author":"I Oswald","year":"1982","unstructured":"Oswald I, French C, Adam K, Gilham J. Benzodiazepine hypnotics remain effective for 24 weeks. Br Med J (Clin Res Ed). 1982;284(6319):860\u20133. https:\/\/doi.org\/10.1136\/bmj.284.6319.860.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"2","key":"2261_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","volume":"13","author":"MJ Sateia","year":"2017","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307\u201349. https:\/\/doi.org\/10.5664\/jcsm.6470.","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"2261_CR32","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/JCP.0b013e31823fe4bd","volume":"32","author":"AE Nardi","year":"2012","unstructured":"Nardi AE, Freire RC, Mochcovitch MD, Amrein R, Levitan MN, King AL, et al. A randomized, naturalistic, parallel-group study for the long-term treatment of panic disorder with clonazepam or paroxetine. J Clin Psychopharmacol. 2012;32(1):120\u20136. https:\/\/doi.org\/10.1097\/JCP.0b013e31823fe4bd.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"2261_CR33","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jama.1983.03340060045024","volume":"250","author":"K Rickels","year":"1983","unstructured":"Rickels K, Case WG, Downing RW, Winokur A. Long-term diazepam therapy and clinical outcome. JAMA. 1983;250(6):767\u201371. https:\/\/doi.org\/10.1001\/jama.1983.03340060045024.","journal-title":"JAMA"},{"issue":"2","key":"2261_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0165-0327(87)90021-8","volume":"13","author":"DV Sheehan","year":"1987","unstructured":"Sheehan DV. Benzodiazepines in panic disorder and agoraphobia. J Affect Disord. 1987;13(2):169\u201381. https:\/\/doi.org\/10.1016\/0165-0327(87)90021-8.","journal-title":"J Affect Disord"},{"issue":"11","key":"2261_CR35","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1001\/arcpsych.1989.01810110035005","volume":"46","author":"LM Nagy","year":"1989","unstructured":"Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavorial group treatment in panic disorder: 2.5-year naturalistic follow-up study. Arch Gen Psychiatry. 1989;46(11):993\u20139. https:\/\/doi.org\/10.1001\/arcpsych.1989.01810110035005.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"2261_CR36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00004714-199308000-00005","volume":"13","author":"MH Pollack","year":"1993","unstructured":"Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer-Brody S, Rosenbaum JF. Long-term outcome after acute treatment with: alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol. 1993;13(4):257\u201363.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"2261_CR37","doi-asserted-by":"publisher","first-page":"12S","DOI":"10.1097\/00004714-199812001-00004","volume":"18","author":"K Rickels","year":"1998","unstructured":"Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol. 1998;18(6):12S-S18.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2261_CR38","first-page":"199","volume":"34","author":"IIIJ Worthington","year":"1998","unstructured":"Worthington IIIJ, Pollack MH, Otto MW, McLean RY. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull. 1998;34(2):199.","journal-title":"Psychopharmacol Bull"},{"issue":"7","key":"2261_CR39","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1176\/appi.ps.54.7.1006","volume":"54","author":"SB Soumerai","year":"2003","unstructured":"Soumerai SB, Simoni-Wastila L, Singer C, Mah C, Gao X, Salzman C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. Psychiatr Serv. 2003;54(7):1006\u201311.","journal-title":"Psychiatr Serv"},{"issue":"1","key":"2261_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/archpsyc.1993.01820130053009","volume":"50","author":"E Schweizer","year":"1993","unstructured":"Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder: I. results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 1993;50(1):51\u201360. https:\/\/doi.org\/10.1001\/archpsyc.1993.01820130053009.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"2261_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/acps.13439","volume":"146","author":"SJ Chathanchirayil","year":"2022","unstructured":"Chathanchirayil SJ, Elias A. Long term use of benzodiazepines by patients cared for by primary care physicians in consultation with psychiatrists. Acta Psychiatr Scand. 2022;146(2):165. https:\/\/doi.org\/10.1111\/acps.13439.","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"2261_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003296","volume":"3","author":"IF Tvete","year":"2013","unstructured":"Tvete IF, Bj\u00f8rner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open. 2013;3(10):e003296. https:\/\/doi.org\/10.1136\/bmjopen-2013-003296.","journal-title":"BMJ Open"},{"issue":"9","key":"2261_CR43","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1176\/appi.ps.201500380","volume":"67","author":"S Alessi-Severini","year":"2016","unstructured":"Alessi-Severini S, Bolton JM, Enns MW, Dahl ME, Chateau D, Collins DM, et al. Sustained use of benzodiazepines and escalation to high doses in a Canadian population. Psychiatr Serv. 2016;67(9):1012\u20138. https:\/\/doi.org\/10.1176\/appi.ps.201500380.","journal-title":"Psychiatr Serv"},{"issue":"3","key":"2261_CR44","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1176\/appi.ajp.20230075","volume":"181","author":"TW Rosenqvist","year":"2024","unstructured":"Rosenqvist TW, Wium-Andersen MK, Wium-Andersen IK, J\u00f8rgensen MB, Osler M. Long-term use of benzodiazepines and benzodiazepine-related drugs: a register-based Danish cohort study on determinants and risk of dose escalation. Am J Psychiatry. 2024;181(3):246\u201354. https:\/\/doi.org\/10.1176\/appi.ajp.20230075.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2261_CR45","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/JCP0000000000000740","volume":"37","author":"RC Freire","year":"2017","unstructured":"Freire RC, Amrein R, Mochcovitch MD, Dias GP, Machado S, Versiani M, et al. A 6-year posttreatment follow-up of panic disorder patients: treatment with clonazepam predicts lower recurrence than treatment with paroxetine. J Clin Psychopharmacol. 2017;37(4):429\u201334. https:\/\/doi.org\/10.1097\/JCP0000000000000740.","journal-title":"J Clin Psychopharmacol"},{"key":"2261_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-10-5562-1_2","volume-title":"Substance and non-substance addiction","year":"2017","unstructured":"Zhang X, Shi J, Tao R, editors. Substance and non-substance addiction. Springer; 2017. https:\/\/doi.org\/10.1007\/978-981-10-5562-1_2."},{"key":"2261_CR47","doi-asserted-by":"crossref","unstructured":"Woods JH, Katz JL, Winger G. Benzodiazepines: Use, abuse, and consequence. Pharmacol Rev 1992; 44:151-347","DOI":"10.1016\/S0031-6997(25)00468-5"},{"issue":"2","key":"2261_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF02245824","volume":"118","author":"JH Woods","year":"1995","unstructured":"Woods JH, Winger G. Current benzodiazepine issues. Psychopharmacology. 1995;118(2):107\u201315.","journal-title":"Psychopharmacology"},{"issue":"4","key":"2261_CR49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0376-8716(86)90068-2","volume":"16","author":"H De Wit","year":"1986","unstructured":"De Wit H, Uhlenhuth EH, Johanson CE. Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend. 1986;16(4):341\u201360. https:\/\/doi.org\/10.1016\/0376-8716(86)90068-2.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"2261_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0022-3565(25)31748-9","volume":"210","author":"R Griffiths","year":"1979","unstructured":"Griffiths R, Bigelow GE, Liebson I. Human drug self-administration: double-blind comparison of pentobarbital, diazepam, chlorpromazine and placebo. J Pharmacol Exp Ther. 1979;210(2):301\u201310.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"2261_CR51","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1176\/ajp.146.10.1333","volume":"146","author":"DA Ciraulo","year":"1989","unstructured":"Ciraulo DA, Barnhill JG, Ciraulo AM, Greenblatt DJ, Shader RI. Parental alcoholism as a risk factor in benzodiazepine abuse: a pilot study. Am J Psychiatry. 1989;146(10):1333\u20135. https:\/\/doi.org\/10.1176\/ajp.146.10.1333.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2261_CR52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00004714-199006000-00006","volume":"10","author":"SG McCracken","year":"1990","unstructured":"McCracken SG, De Wit H, Uhlenhuth EH, Johanson CE. Preference for diazepam in anxious adults. J Clin Psychopharmacol. 1990;10(3):190\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"2261_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/BF00217055","volume":"91","author":"H Cappell","year":"1987","unstructured":"Cappell H, Busto U, Kay G, Naranjo CA, Sellers EM, Sanchez-Craig M. Drug deprivation and reinforcement by diazepam in a dependent population. Psychopharmacology. 1987;91(2):154\u201360.","journal-title":"Psychopharmacology"},{"key":"2261_CR54","unstructured":"Lucki I, Volpicelll JR, Schweizer E. Differential craving between recovering abstinent alcoholic-dependent subjects and therapeutic users of benzodiazepines. In: Problems of Drug Dependence 1990 Proceeding of the 52nd Annual Scientific Meeting 1991; p. 322."},{"issue":"5","key":"2261_CR55","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.amepre.2018.12.009","volume":"56","author":"AI Geller","year":"2019","unstructured":"Geller AI, Dowell D, Lovegrove MC, McAninch JK, Goring SK, Rose KO, et al. US emergency department visits resulting from nonmedical use of pharmaceuticals, 2016. Am J Prev Med. 2019;56(5):639\u201347. https:\/\/doi.org\/10.1016\/j.amepre.2018.12.009.","journal-title":"Am J Prev Med"},{"issue":"4","key":"2261_CR56","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.2020.22106","volume":"325","author":"ME Hirschtritt","year":"2021","unstructured":"Hirschtritt ME, Olfson M, Kroenke K. Balancing the risks and benefits of benzodiazepines. JAMA. 2021;325(4):347\u20138.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"2261_CR57","first-page":"28","volume":"66","author":"CP O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28\u201333.","journal-title":"J clin Psychiatry"},{"issue":"1","key":"2261_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/105504901750160484","volume":"10","author":"MA Posternak","year":"2001","unstructured":"Posternak MA, Mueller TI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict. 2001;10(1):48\u201368. https:\/\/doi.org\/10.1080\/105504901750160484.","journal-title":"Am J Addict"},{"issue":"2","key":"2261_CR59","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1176\/appi.ps.201800321","volume":"70","author":"DT Maust","year":"2019","unstructured":"Maust DT, Lin LA, Blow FC. Benzodiazepine use and misuse among adults in the United States. Psychiatr Serv. 2019;70(2):97\u2013106. https:\/\/doi.org\/10.1176\/appi.ps.201800321.","journal-title":"Psychiatr Serv"},{"key":"2261_CR60","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/drugalcdep.2019.02.033","volume":"200","author":"VR Votaw","year":"2019","unstructured":"Votaw VR, Geyer R, Rieselbach MM, McHugh RK. The epidemiology of benzodiazepine misuse: a systematic review. Drug Alcohol Depend. 2019;200:95\u2013114. https:\/\/doi.org\/10.1016\/drugalcdep.2019.02.033.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"2261_CR61","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.4088\/JCP.v58n1208","volume":"58","author":"DS Cowley","year":"1997","unstructured":"Cowley DS, Roy Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry. 1997;58(12):4301.","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"2261_CR62","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1177\/0269881119859372","volume":"33","author":"LA Quagliato","year":"2019","unstructured":"Quagliato LA, Cosci F, Shader RI, Silberman EK, Starcevic V, Balon R, et al. Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: a meta-analysis of common side effects in acute treatment. J Psychopharmacol. 2019;33(11):1340\u201351. https:\/\/doi.org\/10.1177\/0269881119859372.","journal-title":"J Psychopharmacol"},{"key":"2261_CR63","unstructured":"Fraser AD, Shaw LC, Kwong TC, Rosano TG. Psychotropic agents: the benzodiazepines. The Clinical Toxicology Laboratory. Contemporary Practice Of Poisoning Evaluation. 2001."},{"issue":"6","key":"2261_CR64","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1586\/17476348.2014.957186","volume":"8","author":"NT Vozoris","year":"2014","unstructured":"Vozoris NT. Do benzodiazepines contribute to respiratory problems? Expert Rev Respir Med. 2014;8(6):661\u20133. https:\/\/doi.org\/10.1586\/17476348.2014.957186.","journal-title":"Expert Rev Respir Med"},{"issue":"2","key":"2261_CR65","first-page":"9","volume":"66","author":"SA Stewart","year":"2005","unstructured":"Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(2):9\u201313.","journal-title":"J Clin Psychiatry"},{"issue":"S1","key":"2261_CR66","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.1111\/j.2125.1979.tb04667.x","volume":"7","author":"JR Wittenborn","year":"1979","unstructured":"Wittenborn JR. Effects of benzodiazepines on psychomotor performance. Br J Clin Pharmacol. 1979;7(S1):61S-S67. https:\/\/doi.org\/10.1111\/j.2125.1979.tb04667.x.","journal-title":"Br J Clin Pharmacol"},{"key":"2261_CR67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/genhosppsych.2025.02.004","volume":"94","author":"K Shishida","year":"2025","unstructured":"Shishida K, Nishimura W, Shimomura Y, Murayama M, Yoshimura K, Uchida H, et al. Risk of falls associated with non-GABAergic hypnotics and benzodiazepines in hospitalized patients. Gen Hosp Psychiatry. 2025;94:10\u20135. https:\/\/doi.org\/10.1016\/genhosppsych.2025.02.004.","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"2261_CR68","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/541999-022-00731-4","volume":"14","author":"A Capiau","year":"2023","unstructured":"Capiau A, Huys L, van Poelgeest E, van der Velde N, Petrovic M, Somers A, et al. Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review. Eur Geriatr Med. 2023;14(4):697\u2013708. https:\/\/doi.org\/10.1007\/541999-022-00731-4.","journal-title":"Eur Geriatr Med"},{"key":"2261_CR69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.maturitas.2017.04.002","volume":"101","author":"MJ D\u00edaz-Guti\u00e9rrez","year":"2017","unstructured":"D\u00edaz-Guti\u00e9rrez MJ, Mart\u00ednez-Cengotitabengoa M, de Adana ES, Cano AI, Mart\u00ednez-Cengotitabengoa MT, Besga A, et al. Relationship between the use of benzodiazepines and falls in older adults: a systematic review. Maturitas. 2017;101:17\u201322.","journal-title":"Maturitas"},{"issue":"5","key":"2261_CR70","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/acps.13610","volume":"148","author":"MP Rozing","year":"2023","unstructured":"Rozing MP, Wium-Andersen MK, Wium-Andersen IK, J\u00f8rgensen TS, J\u00f8rgensen MB, Osler M. Use of hypnotic-sedative medication and risk of falls and fractures in adults: a self-controlled case series study. Acta Psychiatr Scand. 2023;148(5):394\u2013404.","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"2261_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2165\/11539050-000000000-00000","volume":"34","author":"T Dassanayake","year":"2011","unstructured":"Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf. 2011;34(2):125\u201356.","journal-title":"Drug Saf"},{"issue":"3","key":"2261_CR72","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2174\/1574886309666140601210422","volume":"9","author":"CJ Verster","year":"2014","unstructured":"Verster CJ, JAE van de Loo A, Moline LM, Roth T. Middle-of-the-night administration of sleep medication: a critical review of the effects on next morning driving ability. Curr Drug Saf. 2014;9(3):205\u201311.","journal-title":"Curr Drug Saf"},{"issue":"9","key":"2261_CR73","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1592\/phco.24.13.38089","volume":"24","author":"CE Mancuso","year":"2004","unstructured":"Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacother J Human Pharmacol Drug Ther. 2004;24(9):1177\u201385. https:\/\/doi.org\/10.1592\/phco.24.13.38089.","journal-title":"Pharmacother J Human Pharmacol Drug Ther"},{"issue":"5","key":"2261_CR74","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000506868","volume":"89","author":"F Cosci","year":"2020","unstructured":"Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89(5):283\u2013306. https:\/\/doi.org\/10.1159\/000506868.","journal-title":"Psychother Psychosom"},{"issue":"2","key":"2261_CR75","first-page":"62","volume":"104","author":"X Hu","year":"2011","unstructured":"Hu X. Benzodiazepine withdrawal seizures and management. J Okla State Med Assoc. 2011;104(2):62\u20135.","journal-title":"J Okla State Med Assoc"},{"issue":"6","key":"2261_CR76","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1177\/02698811198455799","volume":"33","author":"S Jauhar","year":"2019","unstructured":"Jauhar S, Hayes J, Goodwin GM, Baldwin DS, Cowen PJ, Nutt DJ. Antidepressants, withdrawal, and addiction; where are we now? J Psychopharmacol. 2019;33(6):655\u20139. https:\/\/doi.org\/10.1177\/02698811198455799.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"2261_CR77","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/j.1360-0443.2011.03686.x","volume":"107","author":"M Nielsen","year":"2012","unstructured":"Nielsen M, Hansen EH, G\u00f8tzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re\u2010uptake inhibitors. Addiction. 2012;107(5):900\u20138.","journal-title":"Addiction"},{"issue":"6","key":"2261_CR78","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1159\/000439137","volume":"84","author":"V Starcevic","year":"2015","unstructured":"Starcevic V, Brakoulias V, Viswasam K, Berle D. Inconsistent portrayal of medication dependence, withdrawal and discontinuation symptoms in treatment guidelines for anxiety disorders. Psychother Psychosom. 2015;84(6):379\u201380. https:\/\/doi.org\/10.1159\/000439137.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"2261_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-015-0642-5","volume":"18","author":"M Lader","year":"2016","unstructured":"Lader M, Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. Curr Psychiatry Rep. 2016;18(1):8.","journal-title":"Curr Psychiatry Rep"},{"key":"2261_CR80","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.drugalcdep.2018.04.028","volume":"189","author":"JW Welsh","year":"2018","unstructured":"Welsh JW, Tretyak V, McHugh RK, Weiss RD, Bogunovic O. Adjunctive pharmacologic approaches for benzodiazepine tapers. Drug Alcohol Depend. 2018;189:96\u2013107. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.04.028.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"2261_CR81","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0165-0327(01)00330-5","volume":"70","author":"JE Couv\u00e9e","year":"2002","unstructured":"Couv\u00e9e JE, Timmermans MA, Zitman FG, Dutch Chronic Benzodiazepine Working Group. The long-term outcome of a benzodiazepine discontinuation programme in depressed outpatients. J Affect Disord. 2002;70(2):133\u201341.","journal-title":"J Affect Disord"},{"issue":"6","key":"2261_CR82","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/j.1360-0443.1987.tb01529.x","volume":"82","author":"H Ashton","year":"1987","unstructured":"Ashton H. Benzodiazepine withdrawal: outcome in 50 patients. Br J Addict. 1987;82(6):665\u201371. https:\/\/doi.org\/10.1111\/j.1360-0443.1987.tb01529.x.","journal-title":"Br J Addict"},{"key":"2261_CR83","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221082386","volume":"12","author":"AJ Reid Finlayson","year":"2022","unstructured":"Reid Finlayson AJ, Macoubrie J, Huff C, Foster DE, Martin PR. Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey. Ther Adv Psychopharmacol. 2022;12:20451253221082386.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"2261_CR84","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/JCP0b013e3181dcb2f3","volume":"30","author":"AE Nardi","year":"2010","unstructured":"Nardi AE, Freire RC, Valen\u00e7a AM, Amrein R, de Cerqueira AC, Lopes FL, et al. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment. J Clin Psychopharmacol. 2010;30(1):290\u20133. https:\/\/doi.org\/10.1097\/JCP0b013e3181dcb2f3.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"2261_CR85","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23com14959","volume":"84","author":"E Silberman","year":"2023","unstructured":"Silberman E, Nardi AE, Starcevic V, Balon R, Cosci F, Fava GA, et al. Resolving the paradox of long-term benzodiazepine treatment: toward evidence-based practice guidelines. J Clin Psychiatry. 2023;84(6):49605. https:\/\/doi.org\/10.4088\/JCP.23com14959.","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"2261_CR86","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/070674370605100706","volume":"51","author":"RC Voshaar","year":"2006","unstructured":"Voshaar RC, Gorgels WJ, Mol AJ, Van Balkom AJ, Mulder J, Van De Lisdonk EH, et al. Predictors of long-term benzodiazepine abstinence in participants of a randomized controlled benzodiazepine withdrawal program. Can J Psychiatry. 2006;51(7):445\u201352. https:\/\/doi.org\/10.1177\/070674370605100706.","journal-title":"Can J Psychiatry"},{"issue":"3","key":"2261_CR87","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1177\/S0033291798006540","volume":"28","author":"E Schweizer","year":"1998","unstructured":"Schweizer E, Rickels K, De Martinis N, Case G, Garcia-Espana F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med. 1998;28(3):713\u201320. https:\/\/doi.org\/10.1177\/S0033291798006540.","journal-title":"Psychol Med"},{"issue":"4","key":"2261_CR88","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1192\/bjp.158.4.511","volume":"158","author":"SM Murphy","year":"1991","unstructured":"Murphy SM, Tyrer P. A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry. 1991;158(4):511\u20136. https:\/\/doi.org\/10.1192\/bjp.158.4.511.","journal-title":"Br J Psychiatry"},{"issue":"8339","key":"2261_CR89","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/S0140-6736(83)92355-3","volume":"321","author":"P Tyrer","year":"1983","unstructured":"Tyrer P, Owen R, Dawling S. Gradual withdrawal of diazepam after long-term therapy. Lancet. 1983;321(8339):1402\u20136. https:\/\/doi.org\/10.1016\/S0140-6736(83)92355-3.","journal-title":"Lancet"},{"issue":"10","key":"2261_CR90","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1001\/archpsyc.1990.01810220024003","volume":"47","author":"E Schweizer","year":"1990","unstructured":"Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines: II Effects of gradual taper. Arch Gen Psychiatry. 1990;47(10):908\u201315.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"2261_CR91","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1192\/bjp.bp.105.012039","volume":"188","author":"RC Oude Voshaar","year":"2006","unstructured":"Oude Voshaar RC, Gorgels WJ, Mol AJ, Van Balkom AJ, Mulder J, Van De Lisdonk EH, et al. Long-term outcome of two forms of randomised benzodiazepine discontinuation. Br J Psychiatry. 2006;188(2):188\u20139. https:\/\/doi.org\/10.1192\/bjp.bp.105.012039.","journal-title":"Br J Psychiatry"},{"key":"2261_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005194.pub2","author":"C Denis","year":"2006","unstructured":"Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst Rev. 2006. https:\/\/doi.org\/10.1002\/14651858.CD005194.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2261_CR93","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s11606-019-05098-0","volume":"34","author":"LB Gerlach","year":"2019","unstructured":"Gerlach LB, Strominger J, Kim HM, Maust DT. Discontinuation of chronic benzodiazepine use among adults in the United States. J Gen Intern Med. 2019;34(9):1833\u201340. https:\/\/doi.org\/10.1007\/s11606-019-05098-0.","journal-title":"J Gen Intern Med"},{"key":"2261_CR94","doi-asserted-by":"crossref","unstructured":"Oldenhof E, Mason T, Anderson-Wurf J, Staiger PK. Role of the prescriber in supporting patients to discontinue benzodiazepines: a qualitative study. Br J Gen Pract. 2021.","DOI":"10.3399\/BJGP.2020.1062"},{"key":"2261_CR95","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320932452","volume":"10","author":"PC Groot","year":"2020","unstructured":"Groot PC, van Os J. How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication. Ther Adv Psychopharmacol. 2020;10:2045125320932452.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2261_CR96","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231171518","volume":"13","author":"J van Os","year":"2023","unstructured":"van Os J, Groot PC. Outcomes of hyperbolic tapering of antidepressants. Ther Adv Psychopharmacol. 2023;13:20451253231171518.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"3","key":"2261_CR97","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14728214.2012890735","volume":"17","author":"N Zisapel","year":"2012","unstructured":"Zisapel N. Drugs for insomnia. Expert Opin Emerg Drugs. 2012;17(3):299\u2013317. https:\/\/doi.org\/10.1517\/14728214.2012890735.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"2261_CR98","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1517\/14656566.2012.667074","volume":"13","author":"DJ Greenblatt","year":"2012","unstructured":"Greenblatt DJ, Roth T. Zolpidem for insomnia. Expert Opin Pharmacother. 2012;13(6):879\u201393.","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"2261_CR99","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1177\/026981109106927","volume":"24","author":"DJ Nutt","year":"2010","unstructured":"Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABA A receptor modulators as hypnotics. J Psychopharmacol. 2010;24(11):1601\u201312. https:\/\/doi.org\/10.1177\/026981109106927.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"2261_CR100","first-page":"32","volume":"3","author":"DJ Dobson","year":"2018","unstructured":"Dobson DJ, Dobson KS. Avoidance in the clinic: strategies to conceptualize and reduce avoidant thoughts, emotions, and behaviors with cognitive-behavioral therapy. Pract Innov (Wash D C). 2018;3(1):32.","journal-title":"Pract Innov (Wash D C)"},{"issue":"3","key":"2261_CR101","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1192\/bjp.2020.164","volume":"218","author":"E Silberman","year":"2021","unstructured":"Silberman E, Balon R, Starcevic V, Shader R, Cosci F, Fava GA, et al. Benzodiazepines: it\u2019s time to return to the evidence. Br J Psychiatry. 2021;218(3):125\u20137. https:\/\/doi.org\/10.1192\/bjp.2020.164.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"2261_CR102","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000525208","volume":"91","author":"EK Silberman","year":"2022","unstructured":"Silberman EK. Stigmatization of benzodiazepines: pharmacologic and nonpharmacologic contributions. Psychother Psychosom. 2022;91(5):304\u20136. https:\/\/doi.org\/10.1159\/000525208.","journal-title":"Psychother Psychosom"},{"key":"2261_CR103","volume-title":"Blind spots: when medicine gets it wrong, and what it means for our health","author":"M Makary","year":"2025","unstructured":"Makary M. Blind spots: when medicine gets it wrong, and what it means for our health. Bonnier Books UK; 2025."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02261-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02261-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02261-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:02:44Z","timestamp":1768359764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02261-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02261-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author reports no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data sharing is not applicable to this article as no datasets have been generated or analyzed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Ethics approval was not necessary, as this article does not present findings from research involving human participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Dr. Silberman is the only author and is solely responsible for the content of this manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}